Imipenem E Cilastatina Steriscience

Imipenem, the active ingredient in Imipenem E Cilastatina Steriscience, is a carbapenem antibiotic presented as a powder for solution for injection for intravenous use. It treats serious bacterial infections in hospitalized patients, including intra‑abdominal, urinary, skin, and respiratory infections.

GNH USA supplies Imipenem E Cilastatina Steriscience as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Imipenem/cilastatin is used to treat severe bacterial infections across several organ systems.

- Complicated intra‑abdominal infections: provides broad‑spectrum bacterial eradication in severe abdominal sepsis. - Complicated urinary tract infections: eliminates resistant uropathogens causing pyelonephritis and cystitis. - Complicated skin and soft tissue infections: treats deep tissue infections and cellulitis caused by Gram‑negative and Gram‑positive bacteria. - Lower respiratory tract infections: effective against community‑acquired and hospital‑acquired pneumonia. - Febrile neutropenia: offers rapid bacterial coverage in immunocompromised patients with fever.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional emesis after infusion. - Diarrhea: loose stools, generally self‑limiting. - Rash: mild skin erythema or pruritus. - Headache: transient headache during or after dosing. - Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects: - Seizures: risk increases with high doses or renal impairment. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile‑associated diarrhea: possible severe colitis. - Stevens‑Johnson syndrome: rare severe skin reaction. - Renal toxicity: potential worsening of kidney function. - Neutropenia: marked reduction in neutrophil count.

Imipenem/cilastatin should be used with caution in patients with renal impairment, a history of seizures, or known hypersensitivity to beta‑lactams.

- Renal function: adjust dose in patients with reduced creatinine clearance. - Seizure risk: avoid high doses in patients with CNS disorders. - Allergy: screen for penicillin or carbapenem allergy before administration. - Drug monitoring: observe for signs of superinfection or C. difficile colitis. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store below 25°C: keep in original packaging, protect from moisture and light.

Imipenem/cilastatin may interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Valproic acid: concomitant use can lower valproate levels and precipitate seizures. - Other carbapenems: avoid simultaneous use to prevent additive toxicity. - Probenecid: may increase imipenem concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and renal function. - Anticoagulants: watch for altered INR or bleeding risk. - CNS depressants: observe for enhanced neurotoxic effects.